Sequana Medical Announces January 2021 Investor Conference Schedule
December 17, 2020 01:00 ET
|
Sequana Medical
GHENT, Belgium, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart...
Sequana Medical to Host KOL Event on “The Challenge of Diuretic Resistance in the Management of Heart Failure Patients and the Potential for alfapump® DSR therapy”
December 07, 2020 01:00 ET
|
Sequana Medical
Live webcast with Dr. Jeffrey Testani on 11 December 2020 at 03:00 pm CET / 09:00 am EST GHENT, Belgium, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels:...
Sequana Medical Announces Positive Interim Data From North American Pivotal alfapump® Study (POSEIDON)
November 19, 2020 02:00 ET
|
Sequana Medical
Results from first 13 patients in Roll-In Cohort showed over 90% reduction in mean frequency of therapeutic paracentesis versus baselineIndication of rapid and persistent clinically relevant...
Sequana Medical to present at Jefferies 2020 Virtual London Healthcare Conference
November 12, 2020 01:00 ET
|
Sequana Medical
GHENT, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart...
Sequana Medical Announces Strong Interim Results From RED DESERT alfapump® DSR Study and Provides Business Update
October 22, 2020 01:00 ET
|
Sequana Medical
RED DESERT: Results from first five patients indicate repeated dose alfapump DSR therapy to be safe and effectiveInterim data support DSR hypothesis: kidneys eliminate free water to maintain...
Sequana Medical Appoints Two Additional Experts as Heart Failure Scientific Advisors
October 15, 2020 01:00 ET
|
Sequana Medical
Dr. Felker and Dr. Udelson join current advisors to support the development of alfapump® DSR for the management of fluid overload in patients with heart failure GHENT, Belgium, Oct. 15, 2020 (GLOBE...
Sequana Medical announces September 2020 Investor Conference Schedule
September 09, 2020 01:00 ET
|
Sequana Medical
GHENT, Belgium, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart...
Sequana Medical announces H1 2020 results and provides business update
September 03, 2020 01:00 ET
|
Sequana Medical
POSEIDON – Implants in Canada continue; interim results expected H1 2021RED DESERT – Implants continue; interim results expected Q4 2020 DSR (Direct Sodium Removal) – Fundamental patents allowed in...
Sequana Medical Notice of 2020 Half Year Results and Business Update
August 27, 2020 01:00 ET
|
Sequana Medical
GHENT, Belgium, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart...
Sequana Medical Announces €7.3 Million Debt Financing and Provides Clinical Update
July 28, 2020 01:00 ET
|
Sequana Medical
Cash runway extended into H2 2021 enabling Sequana Medical to reach key near term value inflection pointsPOSEIDON – implants resumed and interim results expected in Q1 2021 (North American pivotal...